← Back to Search

Radiopharmaceutical

DaTSCAN Imaging for Neurodegenerative Disease

Phase 4
Waitlist Available
Led By Bradley Boeve, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up participants will be followed to 1-3 days after scan.
Awards & highlights
Pivotal Trial
Drug Has Already Been Approved
No Placebo-Only Group

Summary

This trial will test whether the DaTscan can help doctors better understand and diagnose neurodegenerative diseases.

Who is the study for?
This trial is for adults aged 40-90 with conditions like Parkinson's, various dementias, or mild cognitive impairment. Participants need a Mini-Mental State Exam (MMSE) score over 10 and can't be on certain meds that affect the test results. Those with dementia must have a caregiver present regularly.
What is being tested?
The study tests DaTscan imaging in patients with neurodegenerative diseases by injecting I-123 Ioflupane before a SPECT scan. It aims to correlate these scans with clinical diagnoses and other brain imaging techniques to better understand these conditions.
What are the potential side effects?
Potential side effects may include allergic reactions related to iodine or the radioligand used in DaTscan, similar to those who might react to seafood allergies. The procedure itself is generally safe but consult your doctor about specific risks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~participants will be followed for 1-3 days after scan.
This trial's timeline: 3 weeks for screening, Varies for treatment, and participants will be followed for 1-3 days after scan. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Correlate the DaTscan findings with clinical diagnosis
Secondary study objectives
Safety of DaTscan imaging

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

8Treatment groups
Experimental Treatment
Group I: REM sleep behavior disorderExperimental Treatment2 Interventions
REM sleep behavior disorder
Group II: Parkinson's DiseaseExperimental Treatment2 Interventions
Parkinson's Disease
Group III: Mild Cognitive ImpairmentExperimental Treatment2 Interventions
Mild Cognitive Impairment
Group IV: Frontotemporal DementiaExperimental Treatment2 Interventions
Frontotemporal Dementia
Group V: Essential TremorExperimental Treatment2 Interventions
Essential Tremor
Group VI: Dementia with Lewy BodiesExperimental Treatment2 Interventions
Dementia with Lewy Bodies
Group VII: Corticobasal DegenerationExperimental Treatment2 Interventions
Corticobasal Degeneration
Group VIII: Alzheimer's DiseaseExperimental Treatment2 Interventions
Alzheimer's Disease

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,337 Previous Clinical Trials
3,060,674 Total Patients Enrolled
Bradley Boeve, MDPrincipal InvestigatorMayo Clinic
5 Previous Clinical Trials
3,390 Total Patients Enrolled

Media Library

I-123 Ioflupane solution injection (Radiopharmaceutical) Clinical Trial Eligibility Overview. Trial Name: NCT01453127 — Phase 4
Parkinson's disease Research Study Groups: Dementia with Lewy Bodies, Parkinson's Disease, Essential Tremor, Mild Cognitive Impairment, REM sleep behavior disorder, Frontotemporal Dementia, Alzheimer's Disease, Corticobasal Degeneration
I-123 Ioflupane solution injection (Radiopharmaceutical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01453127 — Phase 4
~35 spots leftby Dec 2025